Could a diabetes drug curb alcohol cravings in schizophrenia?
NCT ID NCT06939088
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This study tests whether tirzepatide (Mounjaro), a drug used for diabetes and obesity, can help people with both schizophrenia and alcohol use disorder drink less. Researchers will give 108 participants either tirzepatide or a placebo for 16 weeks and track changes in heavy drinking days. They will also use brain scans to see if the drug reduces activity in areas linked to alcohol cravings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Psychiatry, Aalborg University Hospital
RECRUITINGAalborg, Denmark, 9000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Psychiatric Center Copenhagen, Frederiksberg Hospital
RECRUITINGFrederiksberg, Denmark, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirzepatide (Mounjaro)
What this could lead to
If it works, this could point toward a new treatment option for alcohol use disorder in people with schizophrenia, a group with few effective therapies.
What could go wrong
This is an early phase 2 trial with only 108 participants, so results may not apply broadly. The drug may not reduce drinking or brain activity as hoped, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.